Radiofrequency ablation of pulmonary tumors

Laura Crocetti, Riccardo Lencioni

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The development of image-guided percutaneous techniques for local tumor ablation has been one of the major advances in the treatment of solid tumors. Among these methods, radiofrequency (RF) ablation is currently established as the primary ablative modality at most institutions. RF ablation is accepted as the best therapeutic choice for patients with early-stage hepatocellular carcinoma when liver transplantation or surgical resection are not suitable options and is considered as a viable alternate to surgery for inoperable patients with limited hepatic metastatic disease, especially from colorectal cancer. Recently, RF ablation has been demonstrated to be a safe and valuable treatment option for patients with unresectable or medically inoperable lung malignancies. Resection should remain the standard therapy for non-small cell lung cancer (NSCLC) but RF ablation may be better than conventional external-beam radiation for the treatment of the high-risk individual with NSCLC. Initial favourable outcomes encourage combining radiotherapy and RF ablation, especially for treating larger tumors. In the setting of colorectal cancer lung metastases, survival rates provided by RF ablation in selected patients, are substantially higher than those obtained with any chemotherapy regimens and provide indirect evidence that RF ablation therapy improves survival in patients with limited lung metastatic disease.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalEuropean Journal of Radiology
Volume75
Issue number1
DOIs
StatePublished - Jul 2010
Externally publishedYes

Fingerprint

Lung
Neoplasms
Non-Small Cell Lung Carcinoma
Colorectal Neoplasms
Therapeutics
Liver Transplantation
Lung Diseases
Hepatocellular Carcinoma
Lung Neoplasms
Radiotherapy
Survival Rate
Radiation
Neoplasm Metastasis
Drug Therapy
Survival
Liver

Keywords

  • Ablation
  • Lung cancer
  • Radiofrequency
  • Solid tumor
  • Therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Radiofrequency ablation of pulmonary tumors. / Crocetti, Laura; Lencioni, Riccardo.

In: European Journal of Radiology, Vol. 75, No. 1, 07.2010, p. 23-27.

Research output: Contribution to journalArticle

Crocetti, Laura ; Lencioni, Riccardo. / Radiofrequency ablation of pulmonary tumors. In: European Journal of Radiology. 2010 ; Vol. 75, No. 1. pp. 23-27.
@article{256929571fca484da33a6d5d69e52b57,
title = "Radiofrequency ablation of pulmonary tumors",
abstract = "The development of image-guided percutaneous techniques for local tumor ablation has been one of the major advances in the treatment of solid tumors. Among these methods, radiofrequency (RF) ablation is currently established as the primary ablative modality at most institutions. RF ablation is accepted as the best therapeutic choice for patients with early-stage hepatocellular carcinoma when liver transplantation or surgical resection are not suitable options and is considered as a viable alternate to surgery for inoperable patients with limited hepatic metastatic disease, especially from colorectal cancer. Recently, RF ablation has been demonstrated to be a safe and valuable treatment option for patients with unresectable or medically inoperable lung malignancies. Resection should remain the standard therapy for non-small cell lung cancer (NSCLC) but RF ablation may be better than conventional external-beam radiation for the treatment of the high-risk individual with NSCLC. Initial favourable outcomes encourage combining radiotherapy and RF ablation, especially for treating larger tumors. In the setting of colorectal cancer lung metastases, survival rates provided by RF ablation in selected patients, are substantially higher than those obtained with any chemotherapy regimens and provide indirect evidence that RF ablation therapy improves survival in patients with limited lung metastatic disease.",
keywords = "Ablation, Lung cancer, Radiofrequency, Solid tumor, Therapy",
author = "Laura Crocetti and Riccardo Lencioni",
year = "2010",
month = "7",
doi = "10.1016/j.ejrad.2010.04.011",
language = "English (US)",
volume = "75",
pages = "23--27",
journal = "European Journal of Radiology",
issn = "0720-048X",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Radiofrequency ablation of pulmonary tumors

AU - Crocetti, Laura

AU - Lencioni, Riccardo

PY - 2010/7

Y1 - 2010/7

N2 - The development of image-guided percutaneous techniques for local tumor ablation has been one of the major advances in the treatment of solid tumors. Among these methods, radiofrequency (RF) ablation is currently established as the primary ablative modality at most institutions. RF ablation is accepted as the best therapeutic choice for patients with early-stage hepatocellular carcinoma when liver transplantation or surgical resection are not suitable options and is considered as a viable alternate to surgery for inoperable patients with limited hepatic metastatic disease, especially from colorectal cancer. Recently, RF ablation has been demonstrated to be a safe and valuable treatment option for patients with unresectable or medically inoperable lung malignancies. Resection should remain the standard therapy for non-small cell lung cancer (NSCLC) but RF ablation may be better than conventional external-beam radiation for the treatment of the high-risk individual with NSCLC. Initial favourable outcomes encourage combining radiotherapy and RF ablation, especially for treating larger tumors. In the setting of colorectal cancer lung metastases, survival rates provided by RF ablation in selected patients, are substantially higher than those obtained with any chemotherapy regimens and provide indirect evidence that RF ablation therapy improves survival in patients with limited lung metastatic disease.

AB - The development of image-guided percutaneous techniques for local tumor ablation has been one of the major advances in the treatment of solid tumors. Among these methods, radiofrequency (RF) ablation is currently established as the primary ablative modality at most institutions. RF ablation is accepted as the best therapeutic choice for patients with early-stage hepatocellular carcinoma when liver transplantation or surgical resection are not suitable options and is considered as a viable alternate to surgery for inoperable patients with limited hepatic metastatic disease, especially from colorectal cancer. Recently, RF ablation has been demonstrated to be a safe and valuable treatment option for patients with unresectable or medically inoperable lung malignancies. Resection should remain the standard therapy for non-small cell lung cancer (NSCLC) but RF ablation may be better than conventional external-beam radiation for the treatment of the high-risk individual with NSCLC. Initial favourable outcomes encourage combining radiotherapy and RF ablation, especially for treating larger tumors. In the setting of colorectal cancer lung metastases, survival rates provided by RF ablation in selected patients, are substantially higher than those obtained with any chemotherapy regimens and provide indirect evidence that RF ablation therapy improves survival in patients with limited lung metastatic disease.

KW - Ablation

KW - Lung cancer

KW - Radiofrequency

KW - Solid tumor

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=77953873273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953873273&partnerID=8YFLogxK

U2 - 10.1016/j.ejrad.2010.04.011

DO - 10.1016/j.ejrad.2010.04.011

M3 - Article

C2 - 20452739

AN - SCOPUS:77953873273

VL - 75

SP - 23

EP - 27

JO - European Journal of Radiology

JF - European Journal of Radiology

SN - 0720-048X

IS - 1

ER -